New Inhibitors of Indoleamine 2,3-Dioxygenase 1: Molecular Modeling Studies, Synthesis, and Biological Evaluation

Antonio Coluccia, Sara Passacantilli, Valeria Famiglini, Manuela Sabatino, Alexandros Patsilinakos, Rino Ragno, Carmela Mazzoccoli, Lorenza Sisinni, Alato Okuno, Osamu Takikawa, Romano Silvestri, Giuseppe La Regina

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Indoleamine 2,3-dioxygenase 1 (IDO1) is an attractive target for anticancer therapy. Herein, we report a virtual screening study which led to the identification of compound 5 as a new IDO1 inhibitor. In order to improve the biological activity of the identified hit, arylthioindoles 6-30 were synthesized and tested. Among these, derivative 21 exhibited an IC50 value of 7 μM, being the most active compound of the series. Furthermore, compounds 5 and 21 induced a dose-dependent growth inhibition in IDO1 expressing cancer cell lines HTC116 and HT29. Three-dimensional quantitative structure-activity relationship studies were carried out in order to rationalize obtained results and suggest new chemical modifications.

Original languageEnglish
Pages (from-to)9760-9773
Number of pages14
JournalJournal of Medicinal Chemistry
Volume59
Issue number21
DOIs
Publication statusPublished - Nov 10 2016

Fingerprint

Indoleamine-Pyrrole 2,3,-Dioxygenase
Quantitative Structure-Activity Relationship
Inhibitory Concentration 50
Cell Line
Growth
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this

Coluccia, A., Passacantilli, S., Famiglini, V., Sabatino, M., Patsilinakos, A., Ragno, R., ... La Regina, G. (2016). New Inhibitors of Indoleamine 2,3-Dioxygenase 1: Molecular Modeling Studies, Synthesis, and Biological Evaluation. Journal of Medicinal Chemistry, 59(21), 9760-9773. https://doi.org/10.1021/acs.jmedchem.6b00718

New Inhibitors of Indoleamine 2,3-Dioxygenase 1 : Molecular Modeling Studies, Synthesis, and Biological Evaluation. / Coluccia, Antonio; Passacantilli, Sara; Famiglini, Valeria; Sabatino, Manuela; Patsilinakos, Alexandros; Ragno, Rino; Mazzoccoli, Carmela; Sisinni, Lorenza; Okuno, Alato; Takikawa, Osamu; Silvestri, Romano; La Regina, Giuseppe.

In: Journal of Medicinal Chemistry, Vol. 59, No. 21, 10.11.2016, p. 9760-9773.

Research output: Contribution to journalArticle

Coluccia, A, Passacantilli, S, Famiglini, V, Sabatino, M, Patsilinakos, A, Ragno, R, Mazzoccoli, C, Sisinni, L, Okuno, A, Takikawa, O, Silvestri, R & La Regina, G 2016, 'New Inhibitors of Indoleamine 2,3-Dioxygenase 1: Molecular Modeling Studies, Synthesis, and Biological Evaluation', Journal of Medicinal Chemistry, vol. 59, no. 21, pp. 9760-9773. https://doi.org/10.1021/acs.jmedchem.6b00718
Coluccia, Antonio ; Passacantilli, Sara ; Famiglini, Valeria ; Sabatino, Manuela ; Patsilinakos, Alexandros ; Ragno, Rino ; Mazzoccoli, Carmela ; Sisinni, Lorenza ; Okuno, Alato ; Takikawa, Osamu ; Silvestri, Romano ; La Regina, Giuseppe. / New Inhibitors of Indoleamine 2,3-Dioxygenase 1 : Molecular Modeling Studies, Synthesis, and Biological Evaluation. In: Journal of Medicinal Chemistry. 2016 ; Vol. 59, No. 21. pp. 9760-9773.
@article{8a41762a0e6f408391a2f19c89aaf1cb,
title = "New Inhibitors of Indoleamine 2,3-Dioxygenase 1: Molecular Modeling Studies, Synthesis, and Biological Evaluation",
abstract = "Indoleamine 2,3-dioxygenase 1 (IDO1) is an attractive target for anticancer therapy. Herein, we report a virtual screening study which led to the identification of compound 5 as a new IDO1 inhibitor. In order to improve the biological activity of the identified hit, arylthioindoles 6-30 were synthesized and tested. Among these, derivative 21 exhibited an IC50 value of 7 μM, being the most active compound of the series. Furthermore, compounds 5 and 21 induced a dose-dependent growth inhibition in IDO1 expressing cancer cell lines HTC116 and HT29. Three-dimensional quantitative structure-activity relationship studies were carried out in order to rationalize obtained results and suggest new chemical modifications.",
author = "Antonio Coluccia and Sara Passacantilli and Valeria Famiglini and Manuela Sabatino and Alexandros Patsilinakos and Rino Ragno and Carmela Mazzoccoli and Lorenza Sisinni and Alato Okuno and Osamu Takikawa and Romano Silvestri and {La Regina}, Giuseppe",
year = "2016",
month = "11",
day = "10",
doi = "10.1021/acs.jmedchem.6b00718",
language = "English",
volume = "59",
pages = "9760--9773",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "21",

}

TY - JOUR

T1 - New Inhibitors of Indoleamine 2,3-Dioxygenase 1

T2 - Molecular Modeling Studies, Synthesis, and Biological Evaluation

AU - Coluccia, Antonio

AU - Passacantilli, Sara

AU - Famiglini, Valeria

AU - Sabatino, Manuela

AU - Patsilinakos, Alexandros

AU - Ragno, Rino

AU - Mazzoccoli, Carmela

AU - Sisinni, Lorenza

AU - Okuno, Alato

AU - Takikawa, Osamu

AU - Silvestri, Romano

AU - La Regina, Giuseppe

PY - 2016/11/10

Y1 - 2016/11/10

N2 - Indoleamine 2,3-dioxygenase 1 (IDO1) is an attractive target for anticancer therapy. Herein, we report a virtual screening study which led to the identification of compound 5 as a new IDO1 inhibitor. In order to improve the biological activity of the identified hit, arylthioindoles 6-30 were synthesized and tested. Among these, derivative 21 exhibited an IC50 value of 7 μM, being the most active compound of the series. Furthermore, compounds 5 and 21 induced a dose-dependent growth inhibition in IDO1 expressing cancer cell lines HTC116 and HT29. Three-dimensional quantitative structure-activity relationship studies were carried out in order to rationalize obtained results and suggest new chemical modifications.

AB - Indoleamine 2,3-dioxygenase 1 (IDO1) is an attractive target for anticancer therapy. Herein, we report a virtual screening study which led to the identification of compound 5 as a new IDO1 inhibitor. In order to improve the biological activity of the identified hit, arylthioindoles 6-30 were synthesized and tested. Among these, derivative 21 exhibited an IC50 value of 7 μM, being the most active compound of the series. Furthermore, compounds 5 and 21 induced a dose-dependent growth inhibition in IDO1 expressing cancer cell lines HTC116 and HT29. Three-dimensional quantitative structure-activity relationship studies were carried out in order to rationalize obtained results and suggest new chemical modifications.

UR - http://www.scopus.com/inward/record.url?scp=84994853619&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994853619&partnerID=8YFLogxK

U2 - 10.1021/acs.jmedchem.6b00718

DO - 10.1021/acs.jmedchem.6b00718

M3 - Article

AN - SCOPUS:84994853619

VL - 59

SP - 9760

EP - 9773

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 21

ER -